Tillotts Pharma, the Swiss subsidiary of Japan's Zeria Pharmaceutical, has agreed to acquire Haupt Pharma Wülfing GmbH, a pharmaceutical manufacturing site in Gronau, Germany, from contract manufacturer Aenova, Zeria said on 26 October 2026.
Why Tillotts Pharma AG (Zeria Pharmaceutical) is buying Haupt Pharma Wülfing GmbH (from Aenova)
Zeria said bringing production in-house would give Tillotts more direct and flexible control over capacity, production planning and quality, support long-term stable supply of Asacol and add expertise in solid dosage forms, packaging and investigational drugs for future portfolio growth.
Deal terms and financing
The share transfer agreement was signed on 23 October 2026 (Swiss time). Tillotts will acquire all equity interests; the purchase price was not disclosed.
Regulatory approvals and timing
Completion is planned for January 2027 or later, subject to approval by the relevant authorities.
Market context
About 280 people work at the Gronau site, whose revenue fell from €51.0m in 2023 to €41.1m in 2025, according to German press. Tillotts plans to invest €23m in the plant over several years. Zeria bought Tillotts in 2009.
